<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382938</url>
  </required_header>
  <id_info>
    <org_study_id>WIWDICS</org_study_id>
    <nct_id>NCT03382938</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Wound Infiltration in Cesarean Section</brief_title>
  <official_title>Wound Infiltration With Dexmedetomidine in Cesarean Section: Effect on Postoperative Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Attikon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of four different wound infiltration protocols in cesarean section will be
      investigated on parturient' pain intensity, PCA morphine consumption given, side effects and
      parturient' overall satisfaction.

      One group will receive for wound infiltration dexmedetomidine, the second ropivacaine, the
      third dexmedetomidine combined with ropivacaine, while the last one will receive normal
      saline (placebo group).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parturients undergoing scheduled cesarean section under combined spinal-epidural anesthesia
      will be included in the study. Women will be randomly allocated according to the type of the
      solution used for wound infiltration into one of the following four groups using the closed
      envelop method.

      Group DEX: Following the closure of the uterine incision and the rectus fascia, 20 mL
      solution of dexmedetomidine 1γ/kg within Normal Saline will be infiltrated subcutaneously
      along the skin wound edges.

      Group ROPI: Following the closure of the uterine incision and the rectus fascia, 20 mL
      solution of ropivacaine 0.375% will be infiltrated subcutaneously along the skin wound edges.

      Group DEX-ROPI: Following the closure of the uterine incision and the rectus fascia, 20 mL
      solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% will be infiltrated
      subcutaneously along the skin wound edges.

      Placebo Group: Following the closure of the uterine incision and the rectus fascia, 20 ml
      with 0.9 % saline solution will be infiltrated subcutaneously along the skin wound edges.

      In Postanesthesia Care Unit, 2 mg of morphine will be administered bolus epidurally before
      the removal of the epidural catheter. Postoperative analgesia will be managed with the
      systematic administration of intravenous paracetamol 1g x 3 /day, oral celecoxib 200mg x 2
      /day and PCA morphine (1 mg/ml) (setting: bolus dose 1 ml every 7 min). The total morphine
      consumption 24 hours after the PCA device initiation will be recorded.

      Also, ranitidine 50 mg and metoclopramide 10 mg will be given intravenously twice per day,
      while ondansetron 4 mg will be prescribed to be administered intravenously in case of
      postoperative nausea or vomiting (max x 3 times/day).

      Postoperative pain will be assessed in rest and mobilization using the Visual Analogue Scale
      (VAS, 0-10) at 1, 3, 6, 12, 18 and 24 hours after the end of surgery from an anesthesiologist
      who does not know the group assignment. Also, at the same time points, hemodynamic parameters
      of the parturients, side effects (nausea, vomiting, sedation, pruritus) and complications
      (fever, infection in the area of the wound infiltration, bleeding) will be recorded, while 24
      hours postoperatively the overall patient' satisfaction with her postoperative analgesia
      management will be assessed using a 4 point scale.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Double (Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>up to 24 hours after the end of surgery</time_frame>
    <description>Postoperative pain will be assessed in rest and mobilization using the Visual Analogue Scale (VAS, 0-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morphine consumption</measure>
    <time_frame>24 hours after the PCA device initiation will be recorded</time_frame>
    <description>morphine given by PCA (1 mg/ml)(setting: bolus dose 1 ml every 7 min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall patient satisfaction</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>overall patient satisfaction with postoperative analgesia using a 4 point scale</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine - Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9 % saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>WOUND INFILTRATION IN CESAREAN SECTION</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexmed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>WOUND INFILTRATION IN CESAREAN SECTION</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Ropi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine - Ropivacaine</intervention_name>
    <description>WOUND INFILTRATION IN CESAREAN SECTION</description>
    <arm_group_label>Dexmedetomidine - Ropivacaine</arm_group_label>
    <other_name>Dexmed Ropi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0,9% saline</intervention_name>
    <description>placebo WOUND INFILTRATION IN CESAREAN SECTION</description>
    <arm_group_label>0.9 % saline</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnancy &gt;37 weeks, ASA I-II, BMI&lt;35

        Exclusion Criteria:

          -  patient refusal, epilepsy, GERD, morbid obesity, drug allergy, ASA class &gt;2, presence
             of atrioventricular block, severe systemic disease, multiple gestation, high risk
             pregnancy, contraindications to epidural technique, a history of severe systemic
             disease, recreational drug or alcohol use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>2nd Department of Anesthesiology, Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Attikon Hospital</investigator_affiliation>
    <investigator_full_name>Paraskevi Matsota</investigator_full_name>
    <investigator_title>Assoc Prof of Anaesthesiology</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>wound infiltration</keyword>
  <keyword>ceasarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

